EBS

EMERGENT BIOSOLUTIONS INC.

EBS · CIK 1367644 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0.7B
20182025
Net Income$0.1B
20182025
Operating CF$0.2B
20182025
Free Cash Flow$0.2B
20182025

Income Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Revenue$0.7B$1.0B$1.0B$1.1B$1.8B$0.6B$0.4B$0.3B
Cost of Revenue$0.3B$0.7B$0.7B$0.5B$0.4B$0.3B
Gross Profit$0.3B$0.4B$0.1B$0.0B
R&D Expense$0.1B$0.1B$0.1B$0.2B$0.2B$0.2B$0.2B$0.1B
SG&A Expense$0.2B$0.3B$0.4B$0.3B$0.3B$0.3B$0.3B$0.2B
Operating Income$0.1B$-0.1B$-0.7B$-0.2B$0.4B$0.3B$0.1B$0.1B
Net Income$0.1B$-0.2B$-0.8B$-0.2B$0.2B$0.2B$0.0B$0.1B
EPS (Basic)$0.98$-3.60$-14.85$-4.47$4.32$3.51$0.91$1.25
EPS (Diluted)$0.93$-3.60$-14.85$-4.47$4.27$3.44$0.90$1.22

Balance Sheet

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Total Assets$1.3B$1.4B$1.8B$3.2B$3.0B$2.9B$2.3B$2.2B
Current Assets$0.7B$0.6B$0.7B$1.2B$1.3B$1.2B$0.7B$0.6B
Cash & Equivalents$0.2B$0.1B$0.1B$0.6B$0.6B$0.6B$0.2B$0.1B
Total Liabilities$0.8B$0.9B$1.2B$1.8B$1.3B$1.4B$1.2B$1.2B
Current Liabilities$0.1B$0.2B$0.7B$1.2B$0.4B$0.4B$0.2B$0.2B
Stockholders' Equity$0.5B$0.5B$0.6B$1.4B$1.6B$1.4B$1.1B

Cash Flow Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Operating Cash Flow$0.2B$0.1B$-0.2B$-0.0B$0.3B$0.5B$0.2B$0.0B
Investing Cash Flow$0.1B$0.1B$0.2B$-0.4B$-0.2B$-0.2B$-0.1B$-0.9B
Capital Expenditures$0.0B$0.0B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B
Financing Cash Flow$-0.1B$-0.2B$-0.5B$0.5B$-0.1B$0.1B$-0.0B$0.8B